ARCHIVES

Iniparib Doesn’t Meet Survival, PFS Endpoints In Phase III Trial in Triple-Negative Breast Cancer

This article is from The Cancer Letter archive.

Vol. 34 No. 2 | February 25, 2011

Download PDF Visit The Full Archive

Related Articles

In Brief: Pursell Most Likely To Replace Conte, Foriend Of Cancer Program; DeVita Names Associate

February 15, 1991

Critics of FDA misunderstand Bayesian analysis, statisticians say.

August 5, 2005

John Durant Names ASCO Executive NP; A New Position, New Voice In Washington

December 2, 1994

Spectral Mammography “Like Color vs. Black & White TV”

August 31, 2012

NCI’s New Policy On Costly Research

December 10, 1993

In Brief: NIH Funding For Shannon Awards To Fall, Eight Institutes Decide Not To Participate

August 13, 1993